Literature DB >> 19917205

Treatment of metronidazole-resistant Trichomonas vaginalis.

Linda M Goldman1, Jacqueline A Upcroft, Kimberly Workowski, Andrea Rapkin.   

Abstract

A 58-year-old Caucasian woman presented with a 14-month history of persistent trichomoniasis not responsive to numerous courses of metronidazole and tinidazole. Vaginal secretion samples were obtained for sensitivity testing and treatment recommendations. In vitro susceptibility testing revealed the patient's Trichomonas vaginalis isolate was highly resistant to both metronidazole and tinidazole. She was treated with topical furazolidone and experienced a complete symptomatic cure and culture remained negative 35 days post furazolidone treatment.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19917205     DOI： 10.1071/SH09064

Source DB:  PubMed          Journal:  Sex Health        ISSN： 1448-5028            Impact factor:   2.706


  13 in total

1.  Susceptibility in vitro of clinically metronidazole-resistant Trichomonas vaginalis to nitazoxanide, toyocamycin, and 2-fluoro-2'-deoxyadenosine.

Authors:  Janelle M Wright; Linda A Dunn; Zygmunt Kazimierczuk; Anita G Burgess; Kenia G Krauer; Peter Upcroft; Jacqueline A Upcroft
Journal:  Parasitol Res       Date:  2010-06-09       Impact factor: 2.289

2.  In Vitro Study of the Susceptibility of Clinical Isolates of Trichomonas vaginalis to Metronidazole and Secnidazole.

Authors:  Arindam P Ghosh; Cheri Aycock; Jane R Schwebke
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

3.  Comprehensive characterization of purine and pyrimidine transport activities in Trichomonas vaginalis and functional cloning of a trichomonad nucleoside transporter.

Authors:  Manal J Natto; Yukiko Miyamoto; Jane C Munday; Tahani A AlSiari; Mohammed I Al-Salabi; Neils B Quashie; Anthonius A Eze; Lars Eckmann; Harry P De Koning
Journal:  Mol Microbiol       Date:  2021-11-20       Impact factor: 3.501

4.  Metronidazole-loaded nanoparticulate thermoreversible gel for gynecologic infection of Trichomonas vaginalis.

Authors:  Ling Fang; Xianyi Lu; Chengjun Cui; Qifeng Shi; Haojue Wang
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

5.  Trichomonas vaginalis contact-dependent cytolysis of epithelial cells.

Authors:  Gila Lustig; Christopher M Ryan; W Evan Secor; Patricia J Johnson
Journal:  Infect Immun       Date:  2013-02-19       Impact factor: 3.441

Review 6.  Getting trichy: tools and approaches to interrogating Trichomonas vaginalis in a post-genome world.

Authors:  Melissa D Conrad; Martina Bradic; Sally D Warring; Andrew W Gorman; Jane M Carlton
Journal:  Trends Parasitol       Date:  2012-12-05

7.  Trichomonas vaginalis flavin reductase 1 and its role in metronidazole resistance.

Authors:  David Leitsch; Brian D Janssen; Daniel Kolarich; Patricia J Johnson; Michael Duchêne
Journal:  Mol Microbiol       Date:  2013-11-20       Impact factor: 3.501

8.  Down-regulation of flavin reductase and alcohol dehydrogenase-1 (ADH1) in metronidazole-resistant isolates of Trichomonas vaginalis.

Authors:  David Leitsch; Mirjana Drinić; Daniel Kolarich; Michael Duchêne
Journal:  Mol Biochem Parasitol       Date:  2012-03-17       Impact factor: 1.759

9.  Gold(I) Phosphine Derivatives with Improved Selectivity as Topically Active Drug Leads to Overcome 5-Nitroheterocyclic Drug Resistance in Trichomonas vaginalis.

Authors:  Yukiko Miyamoto; Shubhangi Aggarwal; Jeff Joseph A Celaje; Sozaburo Ihara; Jonathan Ang; Dmitry B Eremin; Kirkwood M Land; Lisa A Wrischnik; Liangfang Zhang; Valery V Fokin; Lars Eckmann
Journal:  J Med Chem       Date:  2021-05-11       Impact factor: 8.039

10.  Refractory Trichomoniasis in HIV-positive and HIV-negative Subjects.

Authors:  Megan R Miller; Paul Nyirjesy
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.663
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.